Does Dr. DARREN KEMPTON have financial conflicts of interest?

Dr. DARREN KEMPTON (MD, PT) has received a total of $4,749 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $3,512 in personal promotional payouts (consulting, meals, travel) and $1,236 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. DARREN KEMPTON?

According to CMS Open Payments data, Dr. DARREN KEMPTON received funding from REGENERON PHARMACEUTICALS ($1,236), GENZYME CORPORATION ($991), and INCYTE CORPORATION ($376).

Does Dr. DARREN KEMPTON receive research grants or speaking fees?

Dr. DARREN KEMPTON has received $3,512 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $1,236 in clinical research grants.

DR. DARREN KEMPTON

MD, PTReal-Time Hydrated

Specialty: Student in an Organized Health Care Education/Training Program

Practice Location: DALLAS, TX 75390

NPI Number: 1902233208

LIFETIME INDUSTRY VALUE

$4,749

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. KEMPTON is a verified Student in an Organized Health Care Education/Training Program practitioner based in DALLAS, TX.

Between 2021 and 2025, Dr. KEMPTON had an overall industry promotional and research financial footprint of $4,749 as recorded in the federal CMS Open Payments database.

$3,512 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$1,236 was allocated to sponsored clinical trials and medical research activities.

Dr. KEMPTON's primary funding source is REGENERON PHARMACEUTICALS, which accounts for $1,236 (representing 26% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

REGENERON PHARMACEUTICALS

Rank 1

$1,236

26%

GENZYME CORPORATION

Rank 2

$991

20.9%

INCYTE CORPORATION

Rank 3

$376

7.9%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.